Quick Facts

• Main Use: Used for the management of folate deficiency.
• Additional Use: Prescribed to address conditions related to low folate levels, such as certain types of anemia.
• Supportive Role: May be used as an add-on therapy in specific populations with major depressive disorder who have co-occurring folate deficiency.

---

Tetrafol is a prescription medication used to manage conditions associated with low folate levels in the body. Folate is an essential B vitamin needed for processes like the production of red blood cells. Insufficient folate can lead to a type of decreased red blood cell count, which is commonly referred to as anemia. The medication provides the body with the active form of folate to help restore appropriate levels.

In some clinical settings, Tetrafol is prescribed by healthcare professionals as a supportive treatment. It is used as an adjunctive therapy to standard antidepressant regimens for individuals diagnosed with major depressive disorder who exhibit folate deficiency, which may help support treatment response. The appropriate use of this medication is determined after a healthcare provider assesses the patient's specific nutritional status and overall health profile.

Eligibility Map: Who Can and Cannot Use Tetrafol — Official Regulatory Information

The eligibility profile for Tetrafol (Levomefolate Calcium single-ingredient product) is defined by official governmental labeling, which sets strict exclusions and conditions for its use.

Category	Official Regulatory Statement
Populations for whom use is contraindicated	Patients with known hypersensitivity or allergy to any ingredient in the product [1.1].
Condition-specific eligibility rules	Use is improper therapy for pernicious anemia or other megaloblastic anemias caused by Vitamin B12 deficiency [2.7].
Eligibility-related restrictions	Caution is recommended in patients with a history of bipolar illness [2.5].
Age-related eligibility rules	Adults are the primary use population. Use in children should be under the supervision of a physician, and some labels state the product is not recommended for use with children under the age of twelve [2.6].
Pregnancy and lactation eligibility status	Use in pregnant or lactating patients should occur under the supervision of a physician [2.7].

---

Eligibility Classifications (High-Level)

Category	Regulatory Basis / Classification
Eligibility severity classification	Contraindicated (for hypersensitivity); Improper Therapy (for B12 deficiency); Caution Recommended (for bipolar history) [1.1], [2.5].

---

Connection to the Overall Eligibility Profile

Official regulatory documents define who can and cannot use Tetrafol primarily by an absolute contraindication for patients with hypersensitivity and a crucial restriction against using it as sole therapy for megaloblastic anemias caused by Vitamin B12 deficiency. This deficiency restriction is due to the risk of masking the anemia's blood disorder signs while allowing neurological damage to progress. Eligibility for all patient groups is conditional on administration under the supervision of a licensed medical practitioner.

Interactions with other medicines and products

Officially documented information regarding interactions for Tetrafol (Levomefolate Calcium) is defined by its effects on folate exposure and potential pharmacodynamic effects with other medicinal products. The product is formally contraindicated for use in patients with known hypersensitivity to any of its components.

Interactions Affecting Folate Levels

Certain medicinal products are documented in regulatory labels to significantly alter the amount of circulating folate, which can result in decreased folate plasma levels through pharmacokinetic mechanisms:

• Antiepileptic Drugs (AEDs): Co-administration with agents such as phenytoin, carbamazepine, phenobarbital, and lamotrigine can increase the metabolism of circulating folate and impair its absorption.
• Transporter Inhibitors: The antidepressant fluoxetine is documented to noncompetitively inhibit the active transport mechanism responsible for 5-methyltetrahydrofolate absorption in the intestine.
• Other Folate-Lowering Agents: Medications including oral contraceptives, metformin, certain NSAIDs, and warfarin are officially listed as being associated with lowered serum folate levels.
• Alcohol: Consumption of alcohol in excess is documented to potentially decrease folate plasma concentrations.

Pharmacodynamic Effects

• Antifolate Agents: Co-administration with Dihydrofolate Reductase Inhibitors (DHFRI), such as methotrexate or trimethoprim, may reduce or completely neutralize the antifolate agent’s efficacy.
• Phenytoin Caution: Although no reduced effectiveness of phenytoin has been reported with levomefolate calcium, caution is officially advised due to the risk of related folic acid lowering phenytoin blood levels, according to regulatory labels.

Bypassing the Conversion Pathway

The mechanism of action for Tetrafol (Levomefolate Calcium) is based on its role as the biologically active form of Vitamin B₉, which drives core metabolic cycles integral to cellular function. The active ingredient, L-methyl Folate, is chemically identical to the final metabolite of the natural folate cycle, allowing it to directly enter metabolic pathways without relying on the MTHFR enzyme. This mechanism provides an immediate supply of the active co-factor, thereby bypassing genetic or metabolic rate limitations inherent in the conversion of synthetic folic acid.

Driving Systemic Methylation and Homocysteine Metabolism

As an essential co-substrate for the Methionine Synthase enzyme, L-methyl Folate drives the Methionine Cycle, primarily by donating the methyl group required to convert homocysteine into methionine. This action is central to the metabolism of homocysteine and is required for regenerating S-Adenosylmethionine (SAMe), the universal methyl donor necessary for the synthesis of complex molecules, including DNA and neurotransmitters in the brain.

Dual Central and Peripheral Metabolic Function

L-methyl Folate contributes to metabolic function in both the periphery and the brain. Systemically, the mechanism facilitates DNA replication for rapidly dividing cells, facilitating processes like hematopoiesis (blood cell formation). Centrally, L-methyl Folate is the reduced form that is efficiently transported across the Blood-Brain Barrier (BBB), making the necessary methylation capacity available for neuronal function.

Tetrafol, containing Levomefolate Calcium, is administered exclusively by the oral route as a coated tablet or capsule. As a prescription product, administration is required to be overseen by a licensed medical professional. The standardized adult dosing regimen for the stand-alone preparation typically specifies a dose ranging from 7.5 mg to 15 mg per day.

Administration is structured around a once-daily schedule, which is intended to maintain consistent systemic levels of the active folate metabolite over time. To support routine adherence, users are advised to take the dose at approximately the same time each day. An important practical instruction is that the medication can be taken with or without food, as this flexibility is part of its administration profile.

The use of this reduced folate often follows a sustained, long-term duration pattern for the maintenance of metabolic support. The tablet or capsule should be swallowed whole with water. There are no general dose modifications for older adults or specific impairment scenarios within the standard clinical descriptions; the final prescribed regimen is primarily determined by the practitioner based on the patient's individual needs.

Research evidence / Overview of Studies for Tetrafol

---

Evidence for Use in Managing Folate Deficiency and Anemia

Research has widely examined the role of B vitamins, including folate, in maintaining healthy bodily function. Tetrafol, which supplies the active form of folate (Levomefolate Calcium), was studied for its role in managing conditions associated with low folate levels, such as certain types of anemia. The evidence was evaluated in systematic reviews and meta-analyses that look at many studies together, as well as randomized controlled trials (RCTs) where Levomefolate Calcium was compared against standard synthetic folic acid or a placebo.

Studies monitored the restoration of hematological parameters, which was studied for its association with folate supplementation generally. Some head-to-head trials reported a pattern where measurements of red blood cell folate differed between Levomefolate Calcium and folic acid in some specific populations. Reported outcomes were primarily focused on short-term (weeks to months) shifts in laboratory values and biomarkers. The folate class of compounds was studied for its association with correction in deficiency. However, specific, long-term comparative data for this particular formulation remains less consistently documented.

---

Evidence for Use as Adjunctive Support in Major Depressive Disorder (MDD)

Studies explored the use of Tetrafol as an adjunctive therapy—meaning it was used in addition to standard antidepressant medications. This research was often conducted as double-blind, placebo-controlled RCTs. The primary populations evaluated in these trials were adult outpatients who had previously shown an inadequate response to their standard antidepressant treatment.

Research examined patient scores on standardized depression severity scales to understand the patterns observed in the studies. The trials also monitored outcomes such as the percentage of patients who experienced a treatment response or remission. Some trials examined the shift in depression severity scores and tracked the difference between the group receiving Levomefolate Calcium and the group receiving placebo. The observed patterns were most noticeable in patients who received the highest amount studied in the trials, as well as in those with certain metabolic or inflammatory profiles. However, these results apply only to the populations studied, which were often highly selective and treatment-resistant.

Common questions about Tetrafol (FAQ)

Q: What is the main difference between Tetrafol and other similar medicines?

Official documentation describes the active ingredient, L-methyl Folate, as the biologically active form of the B9 vitamin. This compound functions by bypassing the body's natural conversion processes required by synthetic folic acid. This distinction is based on how the body utilizes the nutrient for metabolic function.

Q: Why do people say Tetrafol is a 'next-generation' compound?

The specific labeling of 'next-generation' is an unofficial term, but it is likely related to the ingredient's documented properties. Regulatory background describes L-methyl Folate as a biologically active form that is chemically identical to the body's natural metabolite. This design allows for its immediate utilization without requiring enzymatic conversion.

Q: What are the most commonly reported side effects of Tetrafol?

Official regulatory documents list adverse effects for the compound, but typically do not rank them by exact frequency. Official labels indicate that some reactions, such as headache and nausea, are documented as potential side effects. Severe hypersensitivity or allergic reactions are listed separately as potential serious adverse events.

Q: Are there any food or drink restrictions while using Tetrafol?

Official administration instructions state that the drug can be taken with or without food. Regarding drinks, regulatory labels list that consumption of excessive alcohol may decrease circulating folate levels in the body. No specific restrictions on non-alcoholic drinks are typically noted in the labeling.

Q: Does Tetrafol come in different forms (e.g., tablet, liquid)?

Regulatory dosage and description sections officially describe the product as an oral tablet or capsule. Official labeling does not generally list liquid formulations. Information regarding required dosage form changes must be addressed by the prescribing professional.

Q: Can Tetrafol affect my mood or energy levels?

Official safety notes mention potential mood effects related to the active ingredient, specifically listing caution about mood elevation in patients with a family history of bipolar illness. Regulatory information does not describe effects on mood or energy for the general patient population.

Q: What is the difference between Tetrafol and its metabolites?

Official regulatory documents describe that Tetrafol contains L-methyl Folate, which is chemically identical to the body’s final, biologically active metabolite of Vitamin B9. Unlike synthetic folic acid, this means the active ingredient does not require further conversion steps by the body before it can be used in metabolic pathways.

Q: How does the US FDA classify Tetrafol?

Official regulatory information indicates that the classification of the product can vary depending on its specific formulation and intended use. The FDA classifies the product either as a prescription drug or, in some cases, a prescription dietary supplement known as a 'medical food.' This classification determines the regulatory requirements.

Q: Can Tetrafol cause weight gain or weight loss?

Weight changes are not commonly listed among the officially documented adverse reactions for the single-ingredient formulation. However, regulatory documents for combination products containing the active ingredient have in some instances listed weight gain as a reported adverse event in the postmarketing category.

Q: Is Tetrafol safe for people with kidney or liver issues?

Official prescribing information advises patients to inform their healthcare provider if they have a history of kidney or liver problems. This information is noted in regulatory warnings for products containing levomefolate calcium. Official information notes that the prescribing professional must consider the specific patient situation.

Q: How long was Tetrafol studied before it was approved?

FDA regulatory documents describe clinical study details for the compound. For specific formulations, certain trials included treatment phases lasting up to 24 weeks and subsequent follow-up or elimination phases. The full duration of a drug's pre-market study and review process is varied and complex, as reported in official documentation.

Q: Is Tetrafol a controlled substance?

Regulatory databases, such as those maintained by the US DEA, do not list Levomefolate Calcium, the active ingredient in Tetrafol, as a controlled substance. Controlled substances are drugs regulated by the government due to potential for abuse or dependence.

Q: Is Tetrafol considered a preventative treatment?

The official purpose of Tetrafol is generally described as providing foundational metabolic support. However, official information shows that levomefolate calcium is indicated in certain combination products to raise folate levels for the purpose of reducing the risk of a neural tube defect in a subsequent pregnancy, which is a use-case associated with prevention.

Q: Does taking Tetrafol require routine blood testing?

Regulatory documents emphasize the necessity of ruling out Vitamin B12 deficiency before starting treatment. This is a critical safety constraint due to the risk of masking the condition. Screening for B12 deficiency often involves blood testing.

Q: Can Tetrafol affect the results of other medical tests?

Regulatory warnings indicate that folate can mask the blood-related symptoms of pernicious anemia (Vitamin B12 deficiency). This occurs when folate restores red blood cell counts, thereby affecting the accuracy of blood test readings while potentially allowing progressive neurological damage.

Q: Is Tetrafol a steroid?

No. Official prescribing information classifies the active ingredient, L-methyl Folate, as a Vitamin, specifically a reduced folate compound. It is not classified or referred to as a steroid in any regulatory documents.

Q: Can Tetrafol be used by people with diabetes?

Official prescribing information for products containing levomefolate calcium advises patients to inform their healthcare provider if they have a history of high blood sugar or diabetes. Official information notes that the prescribing professional must consider patient-specific factors when determining the appropriate regimen.

Q: Where can I find the official prescribing information for Tetrafol?

Official documentation for the active ingredient is available on government websites that maintain drug safety data. These include the NIH DailyMed database and the FDA Drugs@FDA database, which provide public access to labeling and safety information.

Q: What are the signs of taking too much Tetrafol (overuse)?

Regulatory documents list general symptoms of allergic reactions and other serious adverse events, which may occur with inappropriate use or high intake. The specific symptoms of folate toxicity are often non-specific. If concerns about potential overuse arise, official information advises following the guidance provided by a healthcare provider.

Q: How long can I use Tetrafol before it expires?

Official storage and use instructions require getting rid of any unused medication after the expiration date printed on the product's packaging. The expiration date reflects the period during which the product is expected to remain stable and meet official quality standards, based on testing by the manufacturer.

Q: Can Tetrafol be crushed or split?

Official regulatory instructions specify that the coated tablet or capsule should be swallowed whole with water. Dissolution testing and product stability are generally based on the intact form of the dosage unit. Official regulatory instructions specify that the dosage unit should be swallowed whole.

How to Store and Dispose of Tetrafol?

The official regulatory documents specify strict conditions for storing and disposing of Tetrafol (L-methyl Folate) to maintain product stability and safety.

Storage Requirements

Tetrafol must be stored at controlled room temperature, maintaining a range of 15°C to 30°C (59°F to 86°F). The medication must be protected from light, moisture, and heat, and should remain in its original, tightly closed container. It is mandatory to keep this product out of the reach of children.

Disposal Instructions

Dispose of any unused or expired Tetrafol in accordance with federal, state, and local regulations. Government guidance recommends using a drug take-back program or mail-back option when available. If not, follow the official instructions for household trash disposal, which involves mixing the drug with an undesirable substance before sealing and discarding.